about
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerGene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysisPositron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis.The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK.Methodological issues in the economic analysis of cancer treatments.Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.Health-state utility values in breast cancer.Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer.Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.Economic impact of hospitalisations among patients in the last year of life: an observational study.The use of surgery in the treatment of ER+ early stage breast cancer in England: Variation by time, age and patient characteristics.Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer.Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?Looking beyond the forest: Using harvest plots, gap analysis, and expert consultations to assess effectiveness, engage stakeholders, and inform policy.The CHD challenge: comparing four cost-effectiveness models.Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.Economic analysis of potentially avoidable hospital admissions in patients with palliative care needsA narrative literature review of the evidence regarding the economic impact of avoidable hospitalizations amongst palliative care patients in the UKQuestions about adjuvant trastuzumab still remainOmission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survivalTumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysisReply: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerBreast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study
P50
Q24652904-C79DAB12-DE6A-49A5-B23D-46E2253C8B34Q27009270-5668D546-6A4F-4AED-AE74-E05AE5D06BE4Q33804681-A33EFC34-60BB-46F6-9229-3A299842DF92Q36445752-77B42F0B-7AF7-4DCE-AA1D-0F3E05169207Q36615450-F846D4AD-2E9E-41CC-AAF0-DBDB59646B66Q36648249-21FB45F1-832D-4C69-AC5E-0F291103A3D7Q37536388-2F6085DC-25A4-4F8E-B306-FE9794595B85Q37555191-D38D8E0E-7AD0-49A6-BAE6-50383BA5CBB5Q37800481-BE197D67-4685-4B46-9DC1-D30F6BB885A8Q37813236-8E3019E1-F44E-440F-947A-539AB040C402Q37833165-FAE8B38D-A8DD-434E-8DFF-3A9925184CB7Q38173728-45879277-3B29-488C-9CD6-7A8B5627A24DQ40043423-4BD87F84-DB72-41A8-AD96-837726B5A9C5Q40815027-5EAF6B72-6568-4A74-8955-19E12F75E1C7Q45216715-E192C6DA-C629-440B-8DF0-4F4CF0795F6EQ45324181-9C860AEA-087F-4D1A-9354-B398E7646C22Q47626296-052661C8-99CC-4869-8F1E-9CAC3925F23DQ51734398-34AD8C14-F78F-4CB0-B952-5A595AD338E1Q54105644-259D6776-3304-44D6-8A73-DC7C0BA07CEDQ58036451-8F13670D-1722-4375-A3A5-79272891FF43Q58036464-797FFA47-984C-4695-8714-AD5398593B29Q59361955-D9A91432-51A2-4938-AD4D-86F277909FACQ88780519-63D5FF9B-9CEF-465A-8BD8-C3EECCA5C8B7Q91542628-77A8447A-08C1-4EC5-B402-EE93ED02C323Q94340397-638C9179-2541-4A0D-8DFD-F8845779A95DQ96132023-5AE2C790-BFA2-48EC-A08C-BD9066AC759A
P50
description
researcher, ORCID id # 0000-0002-3344-0913
@en
wetenschapper
@nl
name
Sue Ward
@ast
Sue Ward
@en
Sue Ward
@es
Sue Ward
@nl
type
label
Sue Ward
@ast
Sue Ward
@en
Sue Ward
@es
Sue Ward
@nl
prefLabel
Sue Ward
@ast
Sue Ward
@en
Sue Ward
@es
Sue Ward
@nl
P106
P1153
7402386094
P31
P496
0000-0002-3344-0913